Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

NCT01700270 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors, Excluding Breast Cancer

Interventions

DRUG: dovitinib (TKI258)
DRUG: fluvoxamine

Sponsor

Novartis Pharmaceuticals